PROVO, Utah, June 17 /PRNewswire-FirstCall/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) announced today the closing of a partial over-allotment option exercise by the underwriters of 569,000 shares of its Class A common stock at $27.00 per share, pursuant to an option granted to the underwriters in connection with its previously announced underwritten secondary public offering of 4.46 million shares of its Class A common stock at $27.00 per share. The shares were sold by three of the Company's founders who currently serve as members of the Company's Board of Directors. No shares were sold by the company, nor did the company receive any proceeds.
J.P. Morgan Securities Inc. and Deutsche Bank Securities Inc. acted as joint book-running managers for the offering. Canaccord Genuity Inc., Stifel, Nicolaus & Company, Incorporated, Avondale Partners, LLC, Sidoti & Company, LLC, and Moelis & Company LLC were co-managers of the offering. The offering of these securities was made by the selling shareholders only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from J.P. Morgan Securities Inc., Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Telephone: 1-866-803-9204; or Deutsche Bank Securities Inc., Attention: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311; Telephone 1-800-503-4611, or by emailing email@example.com.
A shelf registration statement relating to the offering of these securities has previously been filed with the U.S. Securities and Exchange Commission and has become effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its product portfolio, independent business opportunity and corporate social responsibility initiatives. Nu Skin's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company, evidenced in its patent-pending ageLOC™ anti-aging platform and flagship products including the Galvanic Spa® System II, Tru Face® Essence Ultra and LifePak® nano. A global direct selling company, Nu Skin operates in 50 markets worldwide and has more than 765,000 active distributors. Nu Skin is traded on the New York Stock Exchange under the symbol "NUS."
Forward Looking Statement
This press release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the company's results of operation and strategy. These forward-looking statements are based on current information and expectations, and are subject to risks and uncertainties discussed in company filings with the U.S. Securities and Exchange Commission, which could cause the company's actual results to differ materially from expected results. The company undertakes no obligation to publicly update any forward-looking statement contained in this press release, whether as a result of new information, future developments or otherwise, except as may be required by law.
SOURCE Nu Skin Enterprises, Inc.